The Mounjaro 2.5 mg/0.5 ml pen: starter dose, not a trial run

The biggest myth: '2.5 mg is too weak to do anything'

This comes up a lot. People see the six available strengths (2.5, 5, 7.5, 10, 12.5 and 15 mg) and assume that sitting at the bottom means the medicine is barely switched on. That is not how tirzepatide works. The 2.5 mg/0.5 ml pen is not a placebo week and it is not a formality. Tirzepatide is a dual GIP and GLP-1 receptor agonist, and both pathways are active from the first injection. What the 2.5 mg strength does is limit how forcefully the medicine slows gastric emptying in those first weeks, which is the mechanism most responsible for nausea and vomiting at the start of treatment. Think of it less as a low dose and more as the body's settling-in period. The NHS patient information on tirzepatide describes the titration schedule in plain language, and it is consistent with the SmPC: four weeks at 2.5 mg before any increase is considered. Some people do notice appetite changes in week one. Others feel little different until the dose moves up. Both are normal. What is not a good idea is comparing your week-three experience to someone else's week-twelve, the journeys differ, and your prescriber's guidance is what matters, not anecdote.

What the pen contains and how it is given

The Mounjaro KwikPen at 2.5 mg/0.5 ml is a pre-filled, multi-dose device that delivers one pen across four weekly injections, each of 0.5 ml of solution. The injection is subcutaneous, meaning it goes into the fatty tissue just under the skin rather than into muscle. Suitable sites are the abdomen, the front of the thigh, or the upper arm; rotating between sites each week reduces the chance of local reactions at the injection point. The pen is stored in the fridge at 2–8°C, and there is a limited window during which it can be kept at room temperature, the exact duration is in the Patient Information Leaflet that comes with your pen, and that is the figure to follow, not anything you read online. The mechanics of the KwikPen are straightforward: attach a needle, prime as directed, inject, hold for a few seconds, dispose of the needle in a sharps container. If you are new to self-injection, that sounds more involved than it is in practice. Most people find it takes two or three goes before it feels unremarkable. For a fuller picture of how tirzepatide works as a medicine, the Mounjaro overview page covers the mechanism and the evidence in detail.

Side effects that are more common at the start, and when to seek help

The gastrointestinal effects of tirzepatide are most likely to show up when treatment begins or when a dose increases. Nausea is the most commonly reported, followed by diarrhoea, constipation, indigestion and burping. For most people these settle within days to two weeks as the body adjusts, and they are part of the reason the titration exists in the first place. Fatigue and headache are also reported in some patients, particularly in the first week or two. These are not reasons to stop treatment without speaking to your prescriber first. There are, however, symptoms that require prompt medical attention. Severe, persistent stomach pain that radiates to the back (with or without vomiting) is a potential sign of pancreatitis, which the MHRA flagged as a known but infrequent risk in its January 2026 Drug Safety Update on GLP-1 medicines. Signs of an allergic reaction, gallbladder symptoms, and severe dehydration following persistent vomiting or diarrhoea also warrant urgent review. If you are unsure whether a symptom needs attention, contact your prescriber rather than waiting. Mounjaro is a prescription-only medicine, and the clinical relationship that comes with a legitimate prescription (not just the medicine itself) is what makes safe treatment possible.

Moving from 2.5 mg to the next strength

After four weeks at 2.5 mg, your prescriber will review how you have tolerated the starting pen and decide whether to increase to 5 mg. The 5 mg pen begins the therapeutic progression where dose-related weight loss becomes more pronounced in the trial data. The SURMOUNT-1 trial (involving thousands of adults without diabetes, published in the New England Journal of Medicine) reported an average body-weight reduction of around 20–21% over 72 weeks at the 15 mg maintenance dose, with titration following this same step-by-step pathway. Those results were built on the foundation that starts at 2.5 mg. Rushing the schedule does not compress the timeline to those outcomes; it more often means a step back if side effects become unmanageable. Dose decisions remain entirely with your prescriber, who reviews your response and any symptoms before authorising a change, and if you want to understand what the pen at the next major step delivers, you can read about Mounjaro 10 mg/0.5 ml and what that strength involves. If you are curious about what results look like further along the course, the 7.5 mg results page gives a grounded look at what the evidence says at a mid-range dose. What treatment actually costs in the private market is a separate question, the Mounjaro cost context page sets out the honest picture, including what legitimate pricing covers and why the cheapest listing is rarely the right measure for a prescription medicine. When you are ready to see whether tirzepatide is clinically suitable for you, start your free consultation and a GPhC-registered prescriber will review your answers the same day.